🔎 Trials Near Me

Acasă › Leucemie mieloasă acută › Illinois › Chicago

Studii clinice pentru Leucemie mieloasă acută în Chicago, IL

26 studii pentru Leucemie mieloasă acută caută participanți în și în jurul orașului Chicago (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.

Text oficial al studiului (în engleză)

Recrutați pentru un studiu aici? Promovați-l în partea de sus a acestei pagini — $99 pentru 30 de zile →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • și încă 1
Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

În curs de recrutareFaza 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

În curs de recrutareFaza 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

În curs de recrutareFaza 3
  • University of Chicago Medicine, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

În curs de recrutareFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • și încă 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

În curs de recrutareFaza 1
  • Lurie Children's Hospital-Chicago, Chicago
Până la vârsta de 21 · Toate sexele · Actualizat 23 sept. 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

În curs de recrutareFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

În curs de recrutareFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

În curs de recrutareFaza 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de la 18 la 59 · Toate sexele · Actualizat 22 sept. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

În curs de recrutareFaza 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

În curs de recrutareFaza 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Toate sexele · Actualizat 16 sept. 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

În curs de recrutareFaza 1/2
  • University of Chicago, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

În curs de recrutareFaza 3
  • Lurie Children's Hospital-Chicago, Chicago
Vârste de la 1 la 25 · Toate sexele · Actualizat 4 sept. 2026 · NCT07022678

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

În curs de recrutareFaza 3
  • US-Chigago IL-UHCHICAGO, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 sept. 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

În curs de recrutareFaza 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Vârste de la 18 la 75 · Toate sexele · Actualizat 25 aug. 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

În curs de recrutareFaza 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

În curs de recrutareFaza 3
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
29 Days – 21 Years · Toate sexele · Actualizat 24 aug. 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

În curs de recrutareFaza 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

În curs de recrutareStudiu observațional
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • și încă 2
Toate vârstele · Toate sexele · Actualizat 6 iul. 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

În curs de recrutareFaza 1
  • University of Chicago, Chicago
Vârste de 13 ani și peste · Toate sexele · Actualizat 5 mai 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

În curs de recrutareFaza 1/2
  • Northwestern University, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 apr. 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

În curs de recrutareFaza 1/2
  • Northwestern, Chicago
Vârste de 12 ani și peste · Toate sexele · Actualizat 24 mar. 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

În curs de recrutareFaza 1
  • Northwestern Medicine, Chicago
Vârste de 12 ani și peste · Toate sexele · Actualizat 16 mar. 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

În curs de recrutareFaza 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 mar. 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

În curs de recrutareFaza 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2025 · NCT06501196

Studii pentru Leucemie mieloasă acută în alte orașe

Alte studii în Chicago

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.